Possibility of PMX‐DHP therapy as a principal strategy against cytokine storm in COVID‐19: Insights from reconstructed coagulation data

Katagiri et al reported the efficacy and safety of direct hemoperfusion using a polymyxin B-immobilized polystyrene column (PMX-DHP) to control the cytokine storm in COVID-19.1 This report is excellent because the authors tracked urinary β2-microglobulin (β2MG) as a biomarker of cytokines and considers membrane coagulation on the column in relation to systemic abnormal coagulation status. However, we would like to discuss some problems with this...